Abituzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD51 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.